Zheng Chuanxi, Zhou Xiayi, Xu Gang, Qiu Jin, Lan Tao, Li Wei, Zhang Shiquan
Department of Musculoskeletal Oncology, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, 518035, China.
Department of Orthopedics, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Shenzhen, 518035, China.
J Orthop Surg Res. 2025 Feb 18;20(1):174. doi: 10.1186/s13018-025-05589-3.
Preoperative denosumab has been an essential part of the management of giant cell tumor of bone (GCTB) which enhanced subchondral bone integrity and facilitated joint preservation surgery. However, evidence suggests that denosumab-induced sclerotic changes may potentially increase the risk of postoperative recurrence. This study evaluates the efficacy of microwave ablation (MWA) as an adjuvant to intralesional curettage following denosumab treatment in advanced GCTB.
A retrospective review was conducted on 54 patients with extremity GCTB treated with preoperative denosumab between 2019 and 2024. 33 patients underwent curettage, while 21 patients underwent combined microwave ablation with curettage. The recurrence rates and joint preservation rates were analyzed. Functional outcomes were assessed by the Musculoskeletal Tumor Society (MSTS) score.
Local recurrence occurred in 14 patients, including 3 in the MWA group and 11 in the curettage-only group. In the MWA group, all recurrences were managed with repeat curettage, whereas 6 patients in the curettage-only group required extensive resection. The joint preservation rate was significantly higher in the MWA group (100%) compared to the curettage-only group (81.8%). The local recurrence rate was lower in the MWA group (14.3%) than in the curettage-only group (33.3%), with two-year local recurrence-free survival rates of 95.2% and 68.2%, respectively; however, the difference was not statistically significant (P = 0.12). Functional outcomes were comparable, with a mean MSTS score of 24.9 ± 1.33.
The preoperative denosumab combined with adjuvant MWA offers an alternative approach to enhance joint preservation in advanced GCTB, emphasizing its potential as an effective adjuvant strategy. Further large-scale studies are warranted to validate these findings and refine treatment strategies.
术前使用地诺单抗一直是骨巨细胞瘤(GCTB)治疗的重要组成部分,它可增强软骨下骨的完整性并有助于保关节手术。然而,有证据表明,地诺单抗引起的硬化改变可能会增加术后复发的风险。本研究评估了微波消融(MWA)作为晚期GCTB患者接受地诺单抗治疗后病灶内刮除术辅助治疗手段的疗效。
对2019年至2024年间接受术前地诺单抗治疗的54例肢体GCTB患者进行回顾性研究。33例患者接受了刮除术,21例患者接受了刮除术联合微波消融治疗。分析复发率和保关节率。通过肌肉骨骼肿瘤学会(MSTS)评分评估功能结果。
14例患者出现局部复发,其中微波消融组3例,单纯刮除组11例。在微波消融组中,所有复发均通过再次刮除术处理,而单纯刮除组中有6例患者需要进行广泛切除。微波消融组的保关节率(100%)显著高于单纯刮除组(81.8%)。微波消融组的局部复发率(14.3%)低于单纯刮除组(33.3%),两年局部无复发生存率分别为95.2%和68.2%;然而,差异无统计学意义(P = 0.12)。功能结果相当,平均MSTS评分为24.9±1.33。
术前地诺单抗联合辅助微波消融提供了一种增强晚期GCTB保关节的替代方法,强调了其作为有效辅助策略的潜力。需要进一步开展大规模研究来验证这些发现并完善治疗策略。